Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12743MR)

This product GTTS-WQ12743MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12743MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5013MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ5342MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ1008MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ589MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ4460MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ4030MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ6386MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ3914MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW